Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.46 |
| ▸ | ITGAL | P20701 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18050122 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL27731703 | 0.80 | CA2 (0.45) | CA2MAPT | |
| SCHEMBL29742771 | 0.80 | ECE1 (0.47) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL8601335 | 0.80 | ECE1 (0.47) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL29845140 | 0.80 | CA2 (0.45) | CA2MAPT | |
| SCHEMBL30521625 | 0.80 | CA2 (0.45) | CA2MAPT | |
| SCHEMBL3469298 | 0.78 | ECE1 (0.46) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL3821101 | 0.78 | ECE1 (0.46) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL5178911 | 0.78 | ECE1 (0.50) | ITGB2ICAM1ITGALECE1CA2 | |
| SCHEMBL1009371 | 0.78 | ECE1 (0.50) | ITGB2ICAM1ITGALECE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375435-A1 | COMPOUNDS FOR TREATING INFECTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-11 | — | — | US | claimed |
| WO-2023250017-A1 | COMPOUNDS FOR TREATING INFECTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-12-28 | — | — | WO | claimed |
| US-20250375435-A1 | COMPOUNDS FOR TREATING INFECTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2023250017-A1 | COMPOUNDS FOR TREATING INFECTIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375435-A1 | COMPOUNDS FOR TREATING INFECTIONS | PSPH, FBP1, G6PD | ITGB2 1734/4885ICAM1 1464/4885ITGAL 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.